The round, which brings total funding to $21.7m, and was jointly led by the company’s Board of Directors, existing long-term investors and new investment partner and observer Mitsubishi UFJ Capital Co. Ltd.
The company is using the funds to support clinical development of IDCT in the U.S. and Japan, ramp up translation of its cell therapy manufacturing process for Phase III clinical and commercial production, and to fund ongoing operations.
Led by Flagg Flanagan, Chief Executive Officer and Chairman of the Board, DiscGenics is a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine.
Its first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.
FinSMEs
26/09/2017